The Phase 1 and 2 studies of AL001 are completed, and the Phase 3 study of AL001 (NCT04374136) to evaluate the safety and effects of the experimental drug AL001 in people with or at risk for FTD due to a mutation in the GRN gene is ongoing. The gene discussed is GRN; the disease is frontotemporal dementia.